Menu

Recent Interviews

Jerre Foo, Corporate Development Executive, Silkroad Nickel

Jerre Foo
Corporate Development Executive | Silkroad Nickel
50 Armenian Street #03-04, 179938 Singapore (SGP)

enquiries@silkroadnickel.com

+65 6327 8971

Silkroad Nickel: 'The course is set for dynamic profit growth.'


Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG

Dr. Thomas Gutschlag
CEO | Deutsche Rohstoff AG
Q7, 24, 68161 Mannheim (D)

info@rohstoff.de

+49 621 490 817 0

Interview Deutsche Rohstoff AG: "We can imagine additional investments in the field of electromobility."


Steve Cope, President, CEO and Director, Silver Viper

Steve Cope
President, CEO and Director | Silver Viper
1055 W Hastings St Suite 1130, V6E 2E9 Vancouver (CAN)

info@silverviperminerals.com

+1-604-687-8566

Interview with Silver Viper: Future price drivers and takeover fantasy


09. December 2019 | 07:40 CET

Aphria, Aurora Cannabis, Canopy Growth - What Investors Need to Know in December

  • Cannabis
Photo credits: pixabay.com

Investors around the globe have become acquainted with a new industry in recent years: cannabis. It is actually an old plant, but the effects attributed to it have sparked a new trend and brought a variety of applications in various products to market. From Canada, the hype was significantly supported and from there producers have conquered the world - provided that the legal framework for the production, processing or distribution of cannabis products has already been created. After a long phase of rising share prices, the last thing to follow was a hangover mood. Why is December a special month?

time to read: 1 minutes by Mario Hose


 

Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author


Sales at the end of the year 2019

The shares of Aphria have traded between CAD 4.76 and CAD 14.37 over the past 12 months. On Friday, the stock was traded at 6.22 CAD on the Toronto Stock Exchange and recovered significantly from its low around four weeks ago. The stock market value of the cannabis company Aphria at the end of the previous week was CAD 1.57 billion.

At Aurora Cannabis the price development tends to be comparable. The company's shares have been traded between CAD 2.82 and CAD 13.67 since December 2018. Their shares also reached its low for the year around four weeks ago. On Friday, the shares were traded at CAD 3.21 and gave the company a market value of CAD 3.50 billion.

Second row enticing with potential

Canopy Growth, with a market capitalization of CAD 8.61 billion, is the heavyweight among the listed companies in the cannabis industry. Canopy Growth shares have traded from CAD 18.23 to CAD 70.98 over the past 12 months. The indication that the lowest level was reached in the past four weeks is a mere formality. On Friday, the Canopy Growth shares were trading at 24.72 CAD.

There are also exciting second-tier companies that do not yet have to defend a billion-dollar valuation, but are working towards the big breakthrough next year. The developer of cannabis drinks, BevCanna Enterprises, currently has less than CAD 20 million market capitalization and the producer of cannabis in Africa, EXMceuticals, less than CAD 30 million. The two newcomers have promising and scalable business models.

End of the year offers bargains

Investors wishing to position themselves in cannabis may have a particularly interesting window of opportunity for their exposure in the current month of December. Tax Loss Season is a term for experienced investors that stands for tax optimization. The phenomenon of shareholders throwing their loss positions onto the market is a recurring year-end ritual, especially in Canada.

This development is clear in the case of listed companies that have suffered greater price losses in recent months. The chart trend of a loss in value often ends in a panicky sell-off in December. As is well known, the profits lie in purchasing and bargain hunters can get their money's worth with low limits.


Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

04. March 2021 | 09:16 CET | by Stefan Feulner

NanoRepro, EXMceuticals, Deutsche Telekom - The profiteers of the new world!

  • Cannabis

The world has changed since last year. The goal is to fight and contain the virus, which has destroyed our everyday life. In addition to the vaccine manufacturers such as BioNTech, AstraZeneca or Moderna, there are more and more new winners emerging from nowhere to become new stock market stars. Currently, the dominant topic, apart from the vaccination programs that are still hardly taking place in Germany, is the "national testing strategy." At the very least, this should enable a more regular and open life. Be there!

Read

07. December 2020 | 10:01 CET | by André Will-Laudien

EXMceuticals, Aurora, Xphyto Therapeutics - Cannabis 2.0 and Psilocybin!

  • Cannabis

The North American Cannabis Index has brought itself back to life in October! The index lost 80% since the beginning of 2019, but it's going up again with the survivors of the industry. Overall, the capitalization of the sector has decreased by 85%, with the election of Joe Biden, the second buying wave of purchases is underway. If hemp production was the initial focus, it is now the applications, the achieved market access and new active ingredient combinations. In the slipstream of the therapeutic plant customer, another topic came to the fore that has caused investors' hearts to stutter in recent weeks: the psychedelic drugs in the form of psilocybin. Psilocybin has been used as an entheogen and hallucinogenic drug since prehistoric times. Now the medical applications are being investigated. The trend is already running at full speed, the Canadian brokerage house Canaccord estimates the market volume of all indications that are suitable for treatment with active psychedelic ingredients to be USD 100 billion.

Read

15. July 2020 | 12:23 CET | by Mario Hose

BioNTech, EXMceuticals, XPhyto - Covid-19 and legalizations offer potential

  • Cannabis

In recent months, the society around the globe has been going through a process of change of deceleration and standstill. Priorities have been redefined and implemented at record speeds in many places. Covid-19 serves as a catalyst for change for many people. The reasons can be different. The development of corona vaccines and antibody tests will make a lot of money in the future and the legalization of cannabis in the USA on a federal level has the potential to create a renaissance.

Read